==== Front Sci Rep Sci Rep Scientific Reports 2045-2322 Nature Publishing Group UK London 78166 10.1038/s41598-020-78166-9 Article Short-term Cudrania tricuspidata fruit vinegar administration attenuates obesity in high-fat diet-fed mice by improving fat accumulation and metabolic parameters Choi Jun-Hui 1 Kim Myung-Kon 2 Yeo Soo-Hwan 3 Kim Seung seungk@gwangju.ac.kr 1 1 grid.443795.80000 0004 0532 9921Department of Food Science and Biotechnology, Gwangju University, Gwangju, 503-703 Republic of Korea 2 grid.411545.00000 0004 0470 4320Department of Food Science and Technology, Chonbuk National University, Iksan, 570-752 Republic of Korea 3 grid.410912.f0000 0004 0484 6679Fermented Processing Food Science Division, Department of Agrofood Resource, National Academy of Agricultural Science, RDA, Wanju, 55365 Republic of Korea 3 12 2020 3 12 2020 2020 10 2110226 11 2019 18 11 2020 © The Author(s) 2020Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Previous studies have suggested that vinegar intake can help to reduce body fat and hyperglycemia. Therefore, this study aimed to evaluate the anti-obesity efficacy of vinegar fermented using Cudrania tricuspidata fruits (CTFV) and its main phenolic constituents and to analyze its molecular mechanism and changes in obesity-related metabolizing enzymatic activities. We found that HFD significantly caused hepatic steatosis; increases in body fats, feed efficiency, liver mass, lipids, insulin, oxidative parameters, cardiovascular-associated risk indices, lipase and α-amylase activities, whereas CTFV efficaciously attenuated HFD-induced oxidant stress, fat accumulation, obesity-related enzymatic activity, and the activation or reduction of obesity-related molecular reactions via improving metabolic parameters including phosphorylated insulin receptor substrate 1, protein tyrosine phosphatase 1B, phosphorylated phosphoinositide 3-kinase/protein kinase B, phosphorylated mitogen-activated protein kinases, sterol regulatory element-binding protein 1c, CCAAT/enhancer-binding protein, and fatty acid synthase; and decreases in adiponectin receptor 1, leptin receptor, adenosine monophosphate-activated protein kinase, acetyl-CoA carboxylase, and peroxisome proliferator-activated receptor, subsequently ameliorating HFD-induced obesity. Therefore, CTFV might provide a functional food resource or nutraceutical product for reducing body fat accumulation. Subject terms BiochemistryMolecular biologyBiomarkersRural Development Administration (RDA), Republic of KoreaPJ012588032020Gwangju University, Republic of Korea2020G1issue-copyright-statement© The Author(s) 2020 ==== Body Introduction The global obese population is on a constant rise due to a number of factors including a calorific surplus and environmental determinants1, and the global studies are actively conducted on the management and treatment of obesity classified as a disease2,3. An estimated 650 million adults, 13% of the world’s adult population were obese in 2016, and 19.7% of the world’s population will be obese by the year of 20303. In the case of the Republic of Korea, the rate of adult obesity has been on a steady rise to 35.5% in 2016, compared with 25.8% in 1988 and it's expected to increase rapidly by 20304. Recently, as it is recognized that the risk of obesity is high, there is a growing interest in obesity treatment and weight control, and various medicines and herbal medicines for obesity treatment are being developed5,6. Various inhibitor drugs for the treatment of obesity are specifically effective in acting on targeted metabolic diseases, however, these drugs often have side effects such as insomnia, headache, palpitation, irritability, agitation, nervousness, stroke, heart attack, flatulence, diarrhea, abdominal pain, bloating, nausea, dyspepsia, arthralgia, dizziness, constipation, and dry mouth5. Vinegar has long been used in various foods, including medicinal foods; in modern times, it serves as a flavor source for foods in many countries worldwide. The use of such vinegars is expanding due to increased numbers of obese people7–10, the entry into an aging society, an increased national income level11, and an improved quality of life in the Republic of Korea12,13. The commercialization and demand of food production using vinegar for effective fat reduction has steadily increased since, among vinegars, fermented pomegranate fruit vinegar (PFV) was approved by the Korean Food and Drug Administration (KFDA) as a functional ingredient to help reduce body fat for the first time14,15. Several previous studies have shown that vinegar intake reduced the risk factors for high cholesterol and atherosclerosis in rabbits16 and reduced food intake, body weight, and lipid levels in an obese mice model17; furthermore, the acetic acid contained in vinegar affected blood lipid levels and reduced body weight18, and vinegar supplementation reduced glucose levels and postprandial hyperglycemia in clinical study19,20. Recently, vinegar has been reported to show various biological effects, including antimicrobial, antitumor, antioxidant, anti-hepatic fibrosis, and anti-kidney stone recurrence activities as well as effects in reducing body fat and glucose levels21–25. To enhance the efficacy of vinegar, vinegars utilizing some fruits with beneficial health effects have been studied and produced; in fact, it was reported that various fruit types including black raspberries, Schizandra chinensis fruit, Vitis coignetiae fruit, apples, and blueberries were used to develop fruit vinegar13,26,27. Cudrania tricuspidata, which is distributed mostly in East Asia and belongs to the family Morcophyta, is used as a food or medicinal plant. In particular, the fruit of C. tricuspidata is generally consumed as dried or fresh fruits, alcoholic beverages, and jams; additionally, the fruit contain various bio-active substances including flavone, isoflavonoid, and phenolic compounds28. In recent years, studies regarding the anti-obesity effects by C. tricuspidata fruits and its ingredients have been continuously reported28–30. However, there is little information regarding the mechanism and in vitro and in vivo efficacy of C. tricuspidata fruit vinegar (CTFV), and it has yet to be utilized as an ingredient for fermented functional foods. Therefore, the present study was designed to analyze the anti-obesity effects of CTFV and its polyphenolics and to compare the efficacies of CTFV, PFV, and fenofibrate in high-fat diet (HFD)-fed obese mice. Methods Chemicals, reagents, and antibodies Pancreatic lipase, lipoprotein lipase, β-glucosidase, α-amylase, phosphodiesterase type-IV, citrate synthase, alkaline phosphatase, p-nitrophenyl butyrate, p-nitrophenyl-β-D-glucopyranoside, p-nitrophenyl phenylphosphonate (p-NPPPh), acetyl-coenzyme A (acetyl-CoA), 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB), oxaloacetic acid (OAA), p-nitrophenyl phosphate (p-NPP), starch, trizma base, gallic acid, protocatechuic acid, chlorogenic acid, p-hydroxybenzoic acid, caffeic acid, isovanillic acid, rutin, p-coumaric acid, ferulic acid, taxifolin, coumaric acid, rosmarinic acid, quecertin, cinnamic acid, gastrodin, p-hydroxybenzyl alcohol, ethylenediaminetetraacetic acid (EDTA), dimethyl sulfoxide (DMSO), fenofibrate, hematoxylin and eosin, and parishin A, B, C, and E were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), penicillin, and streptomycin were purchased from Invitrogen (Carlsbad, CA, USA). PageRuler TM Plus Prestained protein ladder was purchased from Thermo Scientific (Rockford, IL, USA). Primary antibodies against adiponectin receptor 1 (adipoR1), phosphorylated leptin receptor (pOBR), OBR, phosphorylated insulin receptor substrate 1 (pIRS1), IRS1, phosphorylated extracellular-signal-regulated kinase (pERK), phosphorylated c-Jun N-terminal protein kinase (pJNK), phosphorylated P38 (pP38), phosphorylated phosphoinositide 3-kinase (pPI3K), PI3K, phosphorylated protein kinase B (pAKT), AKT, phosphorylated acetyl-CoA carboxylase (pACC), ACC, phosphorylated adenosine monophosphate-activated protein kinase (pAMPK), AMPK, glucose transporter 4 (GLUT4), sterol regulatory element-binding protein 1c (SREBP1C), peroxisome proliferator-activated receptor α (PPARα), peroxisome proliferator-activated receptor γ (PPARγ), CCAAT/enhancer-binding protein α (CEBPα), CCAAT/enhancer-binding protein β (CEBPβ), fatty acid synthase (FAS), and protein tyrosine phosphatase 1B (PTP1B) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Other reagents were commercially available and of special grade. Wine and vinegar preparation Fresh C. tricuspidata fruits were collected from plants cultivated in a farm located in Milyang district, Gyeongsangnam-do, Republic of Korea and immediately stored at − 20 °C until use. Before preparation of the wine, the frozen fruit was homogenized with tap water at a 1:2 ratio using a multipurpose high-performance hand blender (Lacuzin, China). The sets of mixture were raised to 24°Brix by adding sugar and sterilized for 90 min at 85 °C. The yeast strain (Saccharomyces cerevisiae Fermivin) was cultivated by inoculating into malt medium (12°Brix) and incubating at 25–27 °C for 5 days under shaking at 120 rpm. The fermentation process was then initiated by inoculating 6 L of the homogenized fruit slurry in a 10 L glass jar with 5% of the yeast culture. The fermentation jar was then incubated at 26 °C for 10 days with manual shaking twice daily. At the end of fermentation, the two wine phases (liquid and solid) were separated by centrifugation at 9000×g for 15 min, and the liquid phase was filtered through a 110 mm filter (Whatman filter paper no. 2). The C. tricuspidata fruit wine was then sterilized for 30 min at 85 °C. To prepare the vinegar, equal volumes of the C. tricuspidata fruit wine and traditional starter vinegar (acidity 7.2; described previously31) were mixed and incubated at 30 °C for 60 days. During incubation, fresh wine feeding (half of the volume of the vinegar preparation) and acidity measurements were conducted every twelve days. HPLC analysis HPLC analysis was performed by the previously described method32 using an HPLC system (Waters, Milford, MA, USA) equipped with a 2690 separation module and Waters 996 DAD with a ZORBAX Eclipse XDB-C18 column (250 mm × 4.6 mm, 5 μm; Agilent Technologies, Inc., Santa Clara, CA, USA). For analysis of phenolic acids and flavonoids, the mobile phase comprised 0.1% formic acid in 10% acetonitrile (solvent A) and 0.1% formic acid in 90% acetonitrile (solvent B). The mobile phase ratio was maintained at A:B 100:0 (0–5 min), 100:0 (5–10 min), 88:12 (10–40 min), 30:70 (40–45 min), and 100:0 (45–50 min) at a flow rate of 0.8 mL/min. The UV–Vis absorption spectra were recorded between 200–400 nm during HPLC analysis, and the quantification of individual compounds was based on peak areas at 280 nm. HPLC analysis of parishin derivatives was performed by the previously described method32. The mobile phase comprised 0.1% formic acid in ionized water (solvent A) and 0.1% formic acid in methanol (solvent B). The mobile phase ratio was maintained at A:B 95:5 (0–5 min), 85:15 (5–10 min), 45:55 (10–25 min), and 95:10 (25–40 min) at a flow rate of 0.8 mL/min. The UV–Vis absorption spectra were recorded between 200–400 nm during HPLC analysis, and the quantification of individual compounds was based on peak areas at 220 nm. Twenty phenolic compound standards were used for calibration curves: protocatechuic acid, chlorogenic acid, caffeic acid, isovanillic acid, rutin, p-coumaric acid, ferulic acid, taxifolin, gallic acid, p-hydroxybenzoic acid, coumaric acid, rosmarinic acid, quecertin, cinnamic acid, gastrodin, p-hydroxybenzyl alcohol, and parishin A, B, C, and E. The standard solutions (50, 100, 250, and 500 μg/mL) were prepared in DMSO. The main compounds from CTFV were identified based on the retention times of the standards and quantified by comparing their peak area intensities with those of standard curves. Pancreatic and lipoprotein lipase assay The enzyme activity of pancreatic and lipoprotein lipase was measured by the previously described method30. The enzyme solutions were prepared by adding pancreatic lipase (10 mU) or lipoprotein lipase (10 mU) to 10 mM Tris-HCl (pH 6.8) containing 10 mM MOPS and 5 mM CaCl2 for a total volume of 10 μL. The pancreatic lipase enzymes were pretreated with the extract (10 μg) or each compound (10 μg) in a total volume of 20 μL for 10 min at room temperature (RT). After 10 min pretreatment, the mixtures were added to 80 μL of 3 mM p-nitrophenyl butyrate; then, the reaction was initiated and continued for 30 min at 37 °C. After incubation, the activity of the reaction mixtures was determined by reading the absorbance at 405 nm using a microplate reader (Molecular Devices, Sunnyvale, CA, USA). Furthermore, 1 mU enzymatic activity indicates the enzyme quantity that catalyzes the hydrolysis of 1.0 nmol p-nitrophenyl butyrate per min under assay conditions. 1 Lipaseinhibitoryeffect(%)=Absorbancecontrolwithoutsample-Absorbancecontrolwithsample/Absorbancecontrolwithoutsample×100 β-Glucosidase assay The enzyme activity of β-glucosidase was determined by the previously described method, with slight modification30. The enzyme solution was prepared by adding β-glucosidase (0.1 U) to 10 mM phosphate-buffered saline (PBS) (pH 6.8) for a total volume of 10 μL. The enzyme was pretreated with 10 μL of the extract (10 μg) or each compound (10 μg) for 10 min at RT. After incubation, 80 μL of 3 mM p-nitrophenyl-β-D-glucopyranoside was added to the mixtures, and the reaction was initiated and continued for 10 min at 37 °C. After incubation, the activity of the reaction mixtures was measured by reading the absorbance at 405 nm using a microplate reader. The β-glucosidase inhibitory effect (%) was expressed as the percent difference from the residual activity, as shown in Eq. (1). Furthermore, 1 mU enzymatic activity is defined as the enzyme quantity required to release 1 nmol para-nitrophenol from p-nitrophenyl-β-D-glucopyranoside per min under assay conditions. α-Amylase assay The α-amylase activity analysis was performed by the previously described method33. For use as a specific substrate, 0.3 g starch was dissolved in 1.5 mL of 0.4 M NaOH and heated for 10 min at 98 °C. After cooling in ice, the solution pH was adjusted to 7.0 using 2.0 M HCl in a total volume of 2 mL. The enzyme (10 mU) was pretreated with 10 μL of the extract (10 μg) or each compound (10 μg) in a total volume of 50 μL for 10 min at RT. After incubation, 50 μL of the substrate solution and 50 μL of the reaction solution or each compound were incubated at 35 °C for 30 min. The absorbance of α-amylase enzyme was measured at 580 nm. The α-amylase inhibitory effect (%) was expressed as the percent difference from the residual activity, as shown in Eq. (1). Furthermore, 1 U α-amylase is the enzyme quantity that releases 1.0 mg maltose from starch in 3 min at pH 6.9 at 20 °C. Phosphodiesterase IV assay The enzyme solution was prepared by adding phosphodiesterase IV (2 mU) to 10 mM PBS (pH 6.8) for a total volume of 10 μL according to the previously described method30, and p-NPPPh was used as a specific substrate for phosphodiesterase IV. The substrate solution (10 mM) was prepared by dissolving the substrate in PBS. Phosphodiesterase IV was pretreated with 10 μL of the extract (10 μg) or each compound (10 μg) for 10 min; then, the reaction was initiated and continued for 10 min at 37 °C after adding 10 mM p-NPPPh at a total volume of 100 μL. After incubation, the amount of 4-nitrophenol released was determined by reading the absorbance at 405 nm using a microplate reader. The phosphodiesterase IV inhibitory activity (%) was expressed as the percent difference from the residual activity, as shown in Eq. (1). The enzyme activity was expressed in mU/min, and 1 mU was defined as the enzyme quantity required to hydrolyze 1 nmol p-NPPPh under assay conditions. Citrate synthase assay The enzyme activity of citrate synthase was determined at 412 nm with a microplate reader by the previously described method, with slight modification30. Assays were performed at RT in a solution of 10 mM Tris-HCl buffer (pH 8.0), 0.2 mM acetyl-CoA, 0.3 mM OAA, and 0.1 mM DTNB at a volume of 100 μL. The enzyme (0.05 U) was pretreated with the extract (10 μg) or each compound (10 μg) for 10 min. The reaction was initiated by adding the enzyme (0.05 U) and analyzed by the reaction of CoA with DTNB for 30 min. After 30 min, the inhibitory effect of the extract or each compound was presented as the percent difference from the Vmax (mU/min) of citrate synthase. Finally, 1 mU of activity was defined as the enzyme quantity required to generate 1 nmol CoA per min. 2 Citratesynthaseinhibitioneffect(%)=1-Vmaxcontrolwithsample/Vmaxcontrolwithoutsample×100 Alkaline phosphatase assay Alkaline phosphatase activity was determined by the previously described method, with slight modification34 using a p-NPP liquid substrate system at 405 nm. The enzyme (10 mU) was pretreated with the extract (10 μg) or each compound (10 μg) for 10 min and then treated with 10 mM p-NPP for 15 min at RT. After treatment, the activity of the reaction mixtures was measured by the absorbance values read at 405 nm with a microplate reader by monitoring the release of p-nitrophenol from p-NPP. One unit of alkaline phosphatase activity was defined as 1 μmol p-nitrophenol released per min. The alkaline phosphatase inhibitory effect (%) was expressed as the percent difference from the residual activity, as shown in Eq. (1). Cell culture Cell culture was performed according to the method described35. HepG2, 3T3-L1, and Raw264.7 cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured separately in DMEM supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin. The cells were incubated at 37 °C in humidified air (5% CO2, 95% air). The media were changed every 2 days. The extract was dissolved in saline solution. To examine possible toxic effects, HepG2, 3T3-L1, and Raw264.7 cells were treated with 30–1000 μg/mL CTFV for 24 h. Cell viability assay Cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay according to the method described35. Cells were seeded into 96-well plates at a density of 1 × 104 cells/well and incubated for 24 h before experimental treatments. After treatment with CTFV for the indicated times, MTT was added to each well at a final concentration of 0.5 mg/mL. After incubation at 37 °C for 4 h, the culture media containing MTT were carefully removed. Next, 100 μL dimethyl sulfoxide was added to each well for 10 min to dissolve the formazan crystals, and absorbance was measured at 570 nm using a microplate reader. Wells without cells were used as blanks and were subtracted from each sample as the background. Animals Fifteen-week-old Male Imprinting Control Region (ICR) mice (40–50 g) were used for the high-fat diet (HFD)-fed obese mice model experiment. Four animals were housed per cage and maintained under controlled environmental conditions (22 ± 2 °C, 12 h light/12 h dark cycle). Feed (LabDiet 5L79; ORIENT BIO Inc., Seongnam, Korea) or an HFD with 60% fat (diet-induced obesity (DIO) Rodent Purified Diet w/60%, TestDiet 58Y1; ORIENT BIO Inc., Seongnam, Korea) and tap water were available ad libitum. The compositions of the administered diets are shown in Table 1. Efforts were made to minimize the animals’ suffering and reduce the number of animals used. All experimental procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH publication no. 80–23, revised 1996) and related ethical regulations of Gwangju University, and were approved by the Institutional Animal Care and Use Committee of Jeonnam Institute of Natural Resources Research, Jangheung, South Korea (2018-JINR1814).Table 1 Composition of the experimental diets. Composition w/w Control DIO Feno PFV CTFV Nitrogen-free extract 59.5 37.5 37.5 37.5 37.5 Fat 4.5 34.9 34.9 34.9 34.9 Protein 20.1 23.6 23.6 23.6 23.6 Fiber 4.6 – – – – Ash 5.8 – – – – Mineral mixture 3.5 3 3 3 3 Vitamin mixture 1 1 1 1 1 Fenofibrate – – 0.16 – – PFV – – – 0.4 – CTFV – – – – 0.4 Protein calories 21.0 18.1 18.1 18.1 18.1 Fat calories 13.7 61.6 61.6 61.6 61.6 Carbohydrates calories 65.3 20.3 20.3 20.3 20.3 Energy (kcal/g) 4.04 4.65 4.65 4.91 4.91 The diets composition according to LabDiet 5L79 and TestDiet 58Y1. DIO, high fat diet-induced obese mice DIO group; Feno, Fenofibrate-treated obese mice group; PFV, pomegranates fruits vinegar-treated obese mice group; CTFV, C. tricuspidata fruits vinegar-treated obese mice group. In vivo HFD-fed obese mice model and treatment groups The anti-obesity effect of CTFV was investigated in mice with HFD-induced obesity. The mice were fed an HFD for 50 days, and fenofibrate (Feno) (200 mg/kg/day), PFV (500 mg/kg/day), or CTFV (500 mg/kg/day) were administrated orally for 50 days. The mice were divided into 5 groups with 10 mice per group. Group 1 included normal control mice fed a normal pellet diet and treated with saline as a vehicle (Control group). Group 2 comprised the obese mice model fed the HFD and treated with saline as a vehicle (DIO group). Groups 3, 4, and 5 included the obese mice model treated with Feno (DIO + Feno group), PFV (DIO + PFV), or CTFV (DIO + CTFV), respectively. Food intakes and body weights were recorded at regular 5-day intervals. The body weight gain (g) was calculated as (final biomass − initial biomass)/50 days. The feed efficiency ratio was calculated as biomass gain (final biomass − initial biomass) per mass of feed consumed (total feed supplied—total remaining feed). At the end of the study, after 12 h fasted state the animals in each group were anesthetized using light ether and sacrificed, and several tissues of the liver, kidney, spleen, fats, and blood samples were collected for tissue or biochemical analysis. Serum was obtained from 2 mL of whole blood clotted in test tube and then centrifuged at 1500×g for 15 min. The serum samples were stored at − 70 °C for further experiments. For the measurement of enzymatic activities and oxidative parameters, 10% liver homogenates in cold solution containing 0.5 mM ethylene glycol bis(2-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), 3 mM MgCl2, 10 mM KH2PO4, 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 110 mM sucrose (pH 7.0) were immediately prepared using a homogenizer. The homogenates were centrifuged at 800×g and 4 °C for 5 min. Protein level was measured by bicinchoninic acid (BCA) assay using bovine serum albumin as the standard. Liver and fat tissue histology The white adipose tissue (epididymal, perirenal, and mesenteric fat) of the fat pad and liver were removed in an overnight fasting state and stored at − 70 °C before use. After removal, the liver was perfused in 10% formalin, and the liver and white adipose tissue were fixed in 10% formalin for 24 h. The sections of white adipose tissue were stained with hematoxylin and eosin. The adipocyte size in each group was measured and expressed as a percentage. Fat accumulation in frozen tissue was evaluated histologically using Oil Red O, where the frozen tissue was processed using cryostat, fixed, and stained. The color intensity of Oil Red O staining in each group was analyzed using ImageJ software (National Institutes of Health, Bethesda, MD, USA) and expressed as a percentage. Liver and fat pads were viewed under a Leica DM500 microscope (Leica, Heerbrugg, Switzerland). Catalase assay Catalase (CAT) activity was assayed according to the method described, with modifications36. A mixture of 50 mM sodium phosphate buffer (pH 7.4), 1 μM H2O2, and serum or tissue homogenate formed a final volume of 1 mL, and the decrease in absorbance was measured at 240 nm over 10 min. One unit of CAT activity was defined as the enzyme quantity required to decompose 1 μM H2O2 in 1 min. Enzyme activity was expressed as U/g tissue protein. Superoxide dismutase assay For the superoxide dismutase (SOD) assay, serum or tissue homogenate was mixed with 1 mM xanthine, 0.2 mM cytochrome, and 0.05 M potassium cyanide in 0.05 M potassium phosphate/0.1 mM EDTA buffer by the previously described method37,38. Xanthine oxidase was added to the reaction mixture, and the SOD activity was spectrophotometrically determined at 550 nm with a microplate reader as the inhibitory rate of cytochrome reduction by superoxide radical. Glutathione peroxidase assay The activity of glutathione peroxidase (GPx) was determined by mixing serum or tissue homogenate with 1 mM EDTA, 100 mM GSH, and 5 mM NADPH by the previously described method39, followed by adding 1 U glutathione reductase in 0.1 M phosphate buffer (pH 7.0). After incubation for 3 min, 10 mM cumene hydroperoxide was added, and the oxidation of NADPH into NADP+ was monitored spectrophotometrically at 340 nm, in which 1 U GPx led to the formation of 1 μmol NADP+ per milligram of protein per min. Lipid peroxidation assay The lipid peroxidation assay was carried out using the previously described method, with modifications36. First, 100 μL serum or tissue homogenate was mixed with a reaction mixture containing 30 μL of 0.1 M Tris–HCl buffer (pH 7.4) and 30 μL prooxidative solution (250 μmol/L FeSO4). The volume was adjusted to 300 μL with water before incubation at 37 °C for 1 h. The color reaction was developed by adding 300 μL 8.1% sodium dodecyl sulfate to the reaction mixture containing homogenate. Then, 500 μL acetic acid/HCl (pH 3.4) and 500 μL 0.8% TBA were added. This mixture was incubated at 100 °C for 1 h. The TBA-reactive species produced were measured at 532 nm, and the absorbance was compared with the standard curve prepared using malondialdehyde (MDA). Nitric oxide assay Nitric oxide metabolite in serum or tissue homogenate was measured by the Griess reaction38. First, 100 μL of each sample was incubated with an equal volume of Griess reagent (1% sulfanilamide and 0.1% naphthyl ethylenediamine dihydrochloride in 2.5% polyphosphoric acid) for 10 min at RT. Then, the absorbance was measured at 540 nm with a microplate reader. The nitrite concentration was determined from the absorbance at 540 nm using sodium nitrite as the standard. In vivo metabolizing enzymes assay In vivo enzymatic activities in serums and livers obtained from each group were evaluated by the enzyme assays including pancreatic lipase, lipoprotein lipase, β-glucosidase, α-amylase, phosphodiesterase IV, citrate synthase, and alkaline phosphatase with modifications30,33,34. The serum or liver homogenate were treated with each specific substrate, then, the absorbances of each reaction solution were measured at 405, 412, or 580 nm with a microplate reader. The absorbances were compared with the standard, and the enzymatic activities were expressed in U/mg protein. Biochemical analysis The levels of triacylglycerol (TG) and total protein (TP) in the liver tissue extract and levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL), TG, aspartate aminotransferase (AST), alanine aminotransferase (ALT), glucose, TP, and albumin in serum were determined using a Vitros 250 chemistry system (Ortho Clinical Diagnostics, Raritan, NJ, USA). The low-density lipoprotein cholesterol (LDL) and very LDL (VLDL) levels were calculated using the following formula developed by Friedewald’s formula40: LDL = TC − (HDL − TG/5); VLDL = TG/5. The ratio of HDL and TC (HTR) was calculated as [HTR = HDL/TC]. Serum insulin, leptin, and adiponectin levels were determined using ELISA assay for mouse insulin (Cat. No. EZRMI), mouse leptin (Cat. No. EZML), and mouse adiponectin (Cat. No. EZMADP) (Sigma-Aldrich, St. Louis, MO, USA). The homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated as [fasting serum glucose × fasting serum insulin/22.5] to assess insulin resistance41. The atherogenic index (AI, TG/HDL), atherogenic coefficient (AC, [TC − HDL]/HDL), cardiac risk ratio (CRR, TC/HDL), and coronary artery index (CAI, LDL/HDL) were determined using the equations developed by Ikewuchi & Ikewuchi42. Immunoblotting Immunoblotting analysis was performed according to the method described35. The collected liver tissues were homogenized in normal saline and centrifuged at 10,000×g for 15 min at 4 °C. The protein concentrations were determined by BCA assay. Equal amounts of each tissue extract were separated by 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes. After blocking in 5% non-fat dry milk with Tris-buffered saline/Tween-20 (TBST) buffer (10 mM Tris–HCl, 150 mM NaCl, and 0.1% Tween 20 [pH 7.5]) for 1 h at RT, the membranes were incubated with primary antibodies against adiponectin, leptin, adipoR1, pOBR, OBR, pIRS1, IRS1, pERK, pJNK, pP38, pPI3K, PI3K, AKT, pACC, ACC, pAMPK, AMPK, GLUT4, SREBP1C, PPARα, PPARγ, CEBPα, CEBPβ, FAS, and PTP1B (1:1000 dilution); pAKT (1:2000 dilution); and beta-actin (1:2500 dilution) for 1 h at RT. The membranes were washed three times in TBST buffer and incubated further with horseradish peroxidase-conjugated secondary antibodies for 1 h at RT. To reveal the reaction bands, the membranes were allowed to react with Western Blue Stabilized Substrate for WESTZOL (plus) Western Blot Detection System (Intron Biotechnology, Inc., Seongnam, Korea). The signals were detected by a MicroChemi instrument (DNR Bio-imaging Systems, Jerusalem, Israel). Statistical analysis Statistical analysis was performed by the previously described method30 using SPSS 21 software (SPSS Inc., Chicago, IL, USA). The data collected and analyzed from this study were expressed as mean ± standard deviation (SD). The statistical significance of multiple group comparisons was assessed by one-way analysis of variance followed by a post-hoc Tukey’s test. P-values less than 0.05 were considered as statistically significant. Results CTFV production and physicochemical properties The traditional fermentation method described in the text was applied to produce CTFV, whereas PFV (Daesang Corporation, Seoul, Korea) was brought from the local market to compare their efficacies. The CTF wine was fermented for 10 days and then incubated with a vinegar starter for 60 days. Various physical or chemical properties and alcohol and sugar contents may be changed during the alcoholic and acetic acid fermentation process. The pH values of juice, wine, and vinegar ranged from 3.73–5.44, as shown in Table 2. The highest pH was recorded in CTF juice, and it was reduced in wine and vinegar by pH 3.82 ± 0.04 and pH 3.30 ± 0.06, respectively. The mean sugar content of juice was found to be 24.0 ± 0.1°Brix, which decreased in wine (9.5 ± 0.2°Brix) and vinegar (20.0 ± 0.3°Brix). Table 6 shows that the total acidity of juice was 0.18 ± 0.01%, which increased in wine (0.58 ± 0.02) and vinegar (11.2 ± 0.28) after fermentation and incubation. Moreover, the mean alcohol concentration in wine was 13.0 ± 0.1%, while that in vinegar was 0.0%.Table 2 The physicochemical properties of juice, wine, and vinegar from C. tricuspidata fruits. Fermentation day pH °Brix Total acidity (%) Alcohol (%) Juice 0 5.44 ± 0.49 24.0 ± 0.1 0.18 ± 0.01 0.0 Wine 2 3.94 ± 0.05 23.0 ± 0.3 0.66 ± 0.05 2.2 ± 0.1 4 3.73 ± 0.11 16.0 ± 0.2 0.79 ± 0.06 6.1 ± 0.1 6 3.77 ± 0.10 12.0 ± 0.1 0.60 ± 0.03 11.8 ± 0.1 8 3.81 ± 0.06 10.0 ± 0.1 0.55 ± 0.04 12.1 ± 0.2 10 3.82 ± 0.04# 9.5 ± 0.2# 0.58 ± 0.02# 13.0 ± 0.1# Vinegar 30 3.40 ± 0.05* 14.4 ± 0.4* 7.4 ± 0.23* 0.0 60 3.30 ± 0.06* 20.0 ± 0.3* 11.2 ± 0.28* 0.0 Values are mean ± SD of 3 observations. #p < 0.01, compared with the juice of C. tricuspidata fruits. *p < 0.01, compared with the wine of C. tricuspidata fruits. CTFV contains active ingredients, including polyphenolic and parishin derivatives In previous studies28,32, we found that CTF and its ferment contain various bio-active substances, including flavonoid, phenolic, and parishin derivatives, and exhibit the anti-oxidant and anti-obesity effects of the fruits. Hence, we examined the contents of polyphenolic compounds and parishin derivatives in CTFV using HPLC (Fig. 1A–E). Table 3 shows that the concentrations of gastrodin, p-hydroxybenzoic acid, and parishin A (as parishin derivatives) detected in CTFV were 274.3 ± 2.6, 120.2 ± 0.1, and 10.7 ± 0.4 μg/mL, respectively, at each peak compared to standards, and those of chlorogenic acid, caffeic acid, and rutin (as polyphenolics) were 331.9 ± 5.9, 46.2 ± 1.3, and 142.9 ± 4.2 μg/mL, respectively, compared to standards.Figure 1 HPLC analysis (A–E) and inhibitory effects (F–L) in CTF and CTFV. (A) Mixture of authentic standards. (B) CTF juice before sterilization. (C) CTF juice after sterilization. (D) CTF wine. (E) CTF vinegar. X-axis is retention time in minutes and Y-axis is absorbance unit (AU). (1) gastrodin; (2) p-hydroxybenzyl alcohol; (3) parishin E; (4) parishin B; (5) parishin C; (6) Parishin A (upper-left panel). (1) gallic acid; (2) protocatechuic acid; (3) chlorogenic acid; (4) p-hydroxybenzoic acid; (5) caffeic acid; (6) isovanillic acid; (7) rutin; (8) p-coumaric acid; (9) ferulic acid; (10) taxifolin; (11) trans-coumaric acid; (12) rosmarinic acid; (13) quecertin; 14, trans-cinnamic acid (upper-right panel). After pretreatment with CTFV and the compounds, the mixtures were incubated for 10 or 30 min. After incubation, the activity of the reaction mixtures was determined by the absorbance values read at 405, 412, or 580 nm. The inhibitory effect was expressed as the percent difference from the residual activity by Eq. (1) (Inhibitory effect (%) = [(Absorbance control without sample − Absorbance control with sample)/Absorbance control without sample] × 100) or Eq. (2) ([1 − Vmax control with sample/Vmax control without sample] × 100). Each value is the mean ± SD of triplicate measurements. *p < 0.05 and **p < 0.01, compared to non-treated each enzyme groups. αA, α-amylase; PL, pancreatic lipase; LPL, lipoprotein lipase; ALP, alkaline phosphatase; βG, β-glucosidase; CS, citrate synthase; PDE IV, phosphodiesterase IV. Table 3 Concentration of polyphenolic compounds, total phenol, and total flavonoid of C. tricuspidata fruits at different fermentation steps. Fermentation step Chlorogenic acid Caffeic acid Rutin Gastrodin p-Hydroxybenzoic acid Parishin A Total phenol Total flavonoid Concentration (μg/g dw) Concentration (mg/g dw) CTF juice (before sterilization) 512.8 ± 17.9 29.8 ± 0.0 Trace 1197.4 ± 87.8 Trace Trace 2.32 ± 0.11 0.43 ± 0.03 CTF juice (after sterilization) 540.9 ± 10.7 28.2 ± 0.0 Trace 1574.6 ± 14.6 Trace – 2.33 ± 0.15 0.43 ± 0.03 CTF wine 13% 517.7 ± 8.3 Trace Trace 105.9 ± 3.1 341.2 ± 1.2 – 2.62 ± 0.21 0.58 ± 0.04 CTF vinegar 1423.9 ± 25.3 198.2 ± 5.6 613.0 ± 18.0 1177.3 ± 11.2 515.7 ± 0.4 45.9 ± 1.7 3.55 ± 0.27 0.89 ± 0.07 The data are presented as means ± SD, n = 3. Total phenol content is expressed in mg GAE/g dw. Total flavonoid content is expressed in mg QUE/g dw. CTF, C. tricuspidata fruits; (−) compounds, not detected or not quantified; Trace, trace amounts. CTFV and its major compounds reduce metabolizing enzyme activities in vitro We assayed the inhibition of metabolizing enzymes by determining their enzymatic activity after treatment with the vinegar product and its major substances. The highest concentration of CTFV exerted a reduction in the activities of α-amylase (Fig. 1F), pancreatic lipase (Fig. 1G), lipoprotein lipase (Fig. 1H), alkaline phosphatase (Fig. 1I), β-glucosidase (Fig. 1J), and citrate synthase (Fig. 1K). The inhibitory effects toward the activities of α-amylase, pancreatic lipase, lipoprotein lipase, alkaline phosphatase, and β-glucosidase increased proportionally to the dose at 5–100 μg. The enzymatic activity of phosphodiesterase IV did not differ significantly in any groups treated with CTFV or any compounds (Fig. 1L). All major compounds detected from CTFV inhibited α-amylase, pancreatic lipase, and citrate synthase. In particular, groups treated with chlorogenic acid, p-hydroxybenzoic acid, or parishin A showed strong reductions in pancreatic lipase, β-glucosidase, and citrate synthase activities. Effect of CTFV on cell viability in 3T3-L1, HepG2, and Raw263.7 The effect of CTFV on cell viability was tested by MTT assay of three cell lines: 3T3-L1, HepG2, and Raw263.7. Each cell line was treated with several concentrations of 30, 50, 100, 200, 300, 500, 700, and 1000 μg/mL CTFV for 48 h. Although CTFV treatment up to 300 μg/mL showed no effects on the viability of the three lines, 500–1000 μg CTFV decreased the viability of 3T3-L1 (Fig. 2A), HepG2 (Fig. 2B), and Raw264.7 (Fig. 2C).Figure 2 Assessment of cytotoxic effects. MTT assay showing the effect of CTFV on 3T3-L1 (A), HepG2 (B), and Raw264.7 cells (C) viability. Cells were incubated with the compound at different concentrations (0–1000 μg/mL) for 24 h and cell viability was analyzed by MTT reduction assay. Each value is the mean ± SD of triplicate measurements. *p < 0.01, compared with non-treated group. CTFV reduces body weight gain and decreases feed efficiency of HFD-fed obese mice model To determine whether CTFV administration decreases the increase in body weight and feed efficiency in HFD-fed obese mice as a DIO model, body weight and food intake changes were recorded every fifth day. To the obese mice model, we administered CTFV, PFV as a positive control of a functional ingredient approved by the KFDA for fat reduction, or Feno as a second positive control of a lipid-regulating drug from the beginning of the experiment. As the DIO group, mice fed an HFD (TestDiet 58Y1 with 60% fat) for 50 days exhibited increased body weight and daily body weight gain compared to those of the control group, which was fed a normal diet (LabDiet 5L79) (Fig. 3A,B). The CTFV, PFV, and Feno groups displayed significant differences in the reduction in body weight gain compared with the DIO group; additionally, this reduction in the CTFV group was greater than that in the Feno group (Fig. 3C). While there was no significant difference between mean feed intakes (Fig. 3D,E), the HFD resulted in the increase of feed efficiency ratio compared with the Control group (Fig. 3F). CTFV administration reduced the feed efficiency ratio by 0.045 ± 0.003, respectively, compared with the DIO group (0.099 ± 0.006).Figure 3 Effects of CTFV, PFV, and fenofibrate on body weight (A), body weight gain (B), reduction (%) (C), feed intake (D,E), and feed efficiency (F) in high fat-diet (HFD)-induced obese mice. Each value is the mean ± SD (n = 10). #p < 0.01, compared with Control group, *p < 0.01, compared with DIO group, ap < 0.01, compared with DIO + Feno group. Control, non-induced normal group; DIO, diet-induced obesity model group; DIO + Feno, fenofibrate-treated DIO group, DIO + PFV, pomegranate fruit vinegar (PFV)-treated DIO group; DIO + CTFV, C. tricuspidata fruit vinegar (CTFV)-treated DIO group. Effect of CTFV on the mass of liver, kidney, spleen, and fat tissues Table 4 shows the effects of CTFV, PFV, or Feno-administered groups on the weight of liver, kidney, spleen, and fat tissues. The final liver mass of HFD-fed mice was greater than that of the control group, whereas there were no significant changes in kidney and spleen masses. The HFD increased the weight of epididymal, perirenal, and mesenteric fats. However, CTFV administration reduced the mass gain of the liver and several fats, and the PFV and Feno groups showed a reduction in fat mass gain compared with the DIO group.Table 4 Effect on liver, kidney, spleen, and fats tissue weights in high fat diet‑fed obese mice model. Parameters Control DIO DIO + Feno DIO + PFV DIO + CTFV Liver 2.03 ± 0.12 3.40 ± 0.86# 2.10 ± 0.01 2.89 ± 0.75 1.91 ± 0.22* Kidney 0.44 ± 0.02 0.49 ± 0.06 0.40 ± 0.04 0.44 ± 0.06 0.39 ± 0.05 Spleen 0.12 ± 0.01 0.14 ± 0.03 0.10 ± 0.02 0.13 ± 0.02 0.14 ± 0.02 Epididymal fat 0.61 ± 0.10 1.98 ± 0.30## 1.56 ± 0.18 1.20 ± 0.45* 1.26 ± 0.11* Perirenal fat 0.05 ± 0.01 0.22 ± 0.03## 0.17 ± 0.01* 0.13 ± 0.02** 0.14 ± 0.01** Mesenteric fat 0.13 ± 0.01 0.41 ± 0.06## 0.34 ± 0.01 0.32 ± 0.03* 0.27 ± 0.02** The data are presented as means ± SD, n = 10. One-way ANOVA followed by the post hoc Tukey test. #p < 0.05 and ##p < 0.01, compared to Control group. *p < 0.05 and **p < 0.01, compared to DIO group. Feno, fenofibrate; PFV, pomegranates fruits vinegar; CTFV, C. tricuspidata fruits vinegar. CTFV reduces hepatic fat and adipocyte growth in obese mice To investigate the effects of CTFV, PFV, or Feno administration on hepatic fat accumulation and adipocyte expansion, we analyzed the hepatic fat density and mean adipocyte size in each group. As shown in Fig. 4A,B, HFD accelerated a rise in hepatic fat accumulation (133.8 ± 3.6%) and mean adipocyte size (2.90 μm2 × 103), compared with those (100% or 1.43 μm2 × 103) of the Control group. The CTFV-administered group had the lowest mean level of fat density (104.2 ± 7.8%) (Fig. 4C) and smallest mean adipocyte size (1.98 μm2 × 103) (Fig. 4D), compared with the PFV (111.9 ± 8.2% or 2.28 μm2 × 103), and Feno groups (127.0 ± 3.5% or 2.55 μm2 × 103), respectively.Figure 4 Representative histopathological analysis of the livers (A) and adipocyte tissues (B). Effects of CTFV, PFV, and fenofibrate on hepatic fat (C), and size of epididymal adipose tissue (D) in the obese mice were analyzed with H&E, microscope, and ImageJ. Each value is the mean ± SD of triplicate measurements. #p < 0.01, compared with Control group, *p < 0.01, compared with DIO group, ap < 0.01, compared with DIO + Feno group, bp < 0.05, compared with DIO + PFV group. Control, non-induced normal group; DIO, diet-induced obesity model group; DIO + Feno, fenofibrate-treated DIO group, DIO + PFV, pomegranate fruit vinegar (PFV)-treated DIO group; DIO + CTFV, C. tricuspidata fruit vinegar (CTFV)-treated DIO group. Effect of CTFV on oxidative stress parameters in serum Serum oxidative stress parameters including antioxidant enzymes after CTFV, PFV, and Feno administration in obese mice were assessed due to the crucial role of body parts such as blood and liver on oxidative metabolism. As shown in Table 5, the DIO group revealed decreased activity levels of CAT, SOD, and GPx and increased serum levels of MDA and NOx compared with the Control group. However, CTFV or PFV administration upregulated the mean enzymatic activities of CAT and SOD and reduced lipid oxidation and its product. There were no significant changes in the levels of CAT, SOD, GPx, and NOx between each of the Feno, PFV, and CTFV groups.Table 5 Effects on oxidative stress parameters in serum from high-fat diet-fed obese mice model. Parameters Control DIO DIO + Feno DIO + PFV DIO + CTFV CAT 151.73 ± 6.21 135.13 ± 4.59# 137.74 ± 5.64 144.65 ± 4.13 143.99 ± 3.08 SOD 92.55 ± 6.48 76.55 ± 5.36 77.08 ± 6.40 80.22 ± 6.15 83.41 ± 5.84 GPx 13.89 ± 1.58 11.87 ± 0.89 12.56 ± 1.07 12.15 ± 0.86 11.87 ± 1.21 MDA 1.43 ± 0.11 3.28 ± 0.13## 2.19 ± 0.15* 1.75 ± 0.12* 1.92 ± 0.13* NOx 9.22 ± 0.65 10.72 ± 0.24# 10.69 ± 0.48 10.57 ± 0.40 10.51 ± 0.36 The data are presented as means ± SD, n = 10. One-way ANOVA followed by the post hoc Tukey test. #p < 0.05 and ##p < 0.01, compared to Control group. *p < 0.01, compared to DIO group. Feno, fenofibrate; PFV, pomegranates fruits vinegar; CTFV, C. tricuspidata fruits vinegar; CAT, catalase (U/mg protein); SOD, superoxide dismutase (U/mg protein); GPx, glutathione peroxidase (mU/mg protein); MDA, malondialdehyde (nM/mL); NOx, nitrite (nM/mL). Effect of CTFV on lipid, total protein, and oxidative stress parameters in liver As observed in Table 6, HDF leads to changes in hepatic triacylglycerol and total protein. The liver TG and TP levels were higher in the DIO group compared with the Control group. In the Feno, PFV, and CTFV groups, a reduction in liver TG was confirmed; particularly, CTFV administration showed a powerful liver TG-reducing effect compared with the DIO or Control groups.Table 6 Effects on lipid, total protein, and oxidative stress parameters in liver from high-fat diet-fed obese mice model. Parameters Control DIO DIO + Feno DIO + PFV DIO + CTFV Liver TG 0.41 ± 0.02 0.89 ± 0.07## 0.46 ± 0.05* 0.43 ± 0.09** 0.27 ± 0.07* Liver TP 30.0 ± 2.5 42.9 ± 5.6# 35.1 ± 0.5 37.3 ± 1.7 40.8 ± 5.3 CAT 38.05 ± 1.52 26.32 ± 1.28## 27.04 ± 1.16 29.92 ± 1.20* 29.31 ± 1.17 SOD 0.73 ± 0.03 0.46 ± 0.02# 0.45 ± 0.02 0.48 ± 0.02 0.54 ± 0.03* GPx 0.27 ± 0.02 0.15 ± 0.02## 0.19 ± 0.002 0.18 ± 0.008 0.16 ± 0.02 MDA 1.28 ± 0.05 1.66 ± 0.04## 1.51 ± 0.06* 1.40 ± 0.05** 1.43 ± 0.06** NOS 1.97 ± 0.08 2.43 ± 0.07## 2.39 ± 0.05 2.31 ± 0.04 2.28 ± 0.05 The data are presented as means ± SD, n = 10. One-way ANOVA followed by the post hoc Tukey test. #p < 0.05 and ##p < 0.01, compared to Control group. *p < 0.05 and **p < 0.01, compared to DIO group. Feno, fenofibrate; PFV, pomegranates fruits vinegar; CTFV, C. tricuspidata fruits vinegar; TG, triacylglycerol (mg/dL); TP, total protein (mg/dL); CAT, catalase (U/mg protein); SOD, superoxide dismutase (U/mg protein); GPx, glutathione peroxidase (U/mg protein); MDA, malondialdehyde (nM/mL); NOS, nitric oxide synthesis (nM/min/mg protein). The CTFV group had mean increases in CAT, SOD, and GPx activities compared with those of the DIO group, but only the change in SOD showed significance (Table 6). Additionally, this group showed an inhibitory effect against lipid oxidation. In the PFV and Feno groups, significant changes in CAT or MDA levels were observed, while there were no differences in NOS and GPx between each of the Feno, PFV, and CTFV groups. Effect of CTFV on metabolizing enzyme activities in serum The interruption of obesity-related enzymatic activities, including digestive and energy-metabolizing enzymes, might mediate their absorption and energy consumption. In the present study, the mean serum levels of pancreatic lipase, lipoprotein lipase, and alkaline phosphatase from the DIO group of obese mice were increased compared with those of the Control group (Fig. 5). Between the Control and DIO groups, pancreatic lipase showed a significant difference (Fig. 5B), but the other serum enzymes did not. In the serum from obese mice in the CTFV group, pancreatic lipase (20.77 ± 2.11 mU/mg protein) was reduced compared with that of DIO groups (26.18 ± 1.97 mU/mg protein) (Fig. 5B). The Feno and PFV groups showed no significant alteration in the enzymatic activity compared with the DIO group. These findings suggest that HFD causes the activation of pancreatic lipase and CTFV administration inhibits the activities of pancreatic lipase in serum.Figure 5 Effects of CTFV, PFV, and fenofibrate on α-amylase (A,G), pancreatic lipase (B), lipoprotein lipase (C,H), alkaline phosphatase (D,I), β-glucosidase (E,J), and phosphadesterase IV (F,K), and citrate synthase (L) in serum and liver from the obese mice. Each value is the mean ± SD of triplicate measurements. #p < 0.05 and ##p < 0.01, compared with Control group, *p < 0.05 and **p < 0.01, compared with DIO group, ap < 0.05 and aap < 0.01, compared with DIO + Feno group. Control, non-induced normal group; DIO, diet-induced obesity model group; DIO + Feno, fenofibrate-treated DIO group, DIO + PFV, pomegranate fruit vinegar (PFV)-treated DIO group; DIO + CTFV, C. tricuspidata fruit vinegar (CTFV)-treated DIO group. Effect of CTFV on metabolizing enzyme activities in liver We further investigated changes in metabolizing enzyme activities in liver from obese mice administered CTFV, PFV, or Feno. As shown in Fig. 5, HFD caused mean increases in α-amylase and lipoprotein lipase activity in the liver. CTFV administration inhibited the activities of α-amylase (Fig. 5G), lipoprotein lipase (Fig. 5H), and β-glucosidase (Fig. 5J) compared with those of the DIO or Control groups, whereas there were no significant differences in alkaline phosphatase, β-glucosidase, phosphodiesterase IV, and citrate synthase in the CTFV group compared with the DIO group. In the PFV group alone, there were significant changes in α-amylase and lipoprotein lipase activities compared with those of the DIO group (Fig. 5G,H). These findings suggest that HFD causes the activation of α-amylase and lipoprotein lipase, and CTFV administration partially inhibits the increased activities of α-amylase and lipoprotein lipase in the liver. Effect of CTFV on serum biochemical parameters HFD-induced obesity is known to be intimately related with lipid profiles, insulin resistance, adipokines, atherogenesis, and cardiac risk. Table 7 reveals the serum levels of the main biochemical parameters, including lipids, glucose, insulin, proteins, leptin, adiponectin, and some indices. Compared with the Control group, HFD feeding of DIO group mice for 50 days led to enhanced mean levels of all parameters and indices, except for adiponectin, which showed an average decrease; there were no significant differences in HDL, glucose, TP, albumin, leptin, and adiponectin values. CTFV administration reduced the values of lipid metabolic parameters including TC, TG, LDL, and VLDL, and increased the HDL mean value. The Feno group showed strong reductions in TC and LDL values; moreover, the PFV group had decreases in TG and LDL values. Serum insulin levels and insulin resistance of CTFV-administered obese mice were lower than those of the DIO group. Increased serum AST and ALT activities were reduced in the CTFV, PFV, and Feno groups, except for ALT in the Feno group.Table 7 Effects on lipid levels, and related parameters in serum from high-fat diet-fed obese mice model. Parameters Control DIO DIO + Feno DIO + PFV DIO + CTFV TC 100.1 ± 9.2 155.0 ± 6.3# 95.3 ± 5.0** 138.7 ± 7.3 128.3 ± 3.6** TG 150.0 ± 9.4 302.0 ± 14.6# 98.2 ± 3.0** 227.7 ± 7.1** 89.7 ± 12.1** HDL 108.3 ± 3.1 115.7 ± 14.4 109.0 ± 9.8 125.0 ± 8.7 128.0 ± 8.2 LDL 21.7 ± 5.2 99.7 ± 7.5# 5.9 ± 2.1** 59.2 ± 4.5** 18.3 ± 3.4** VLDL 30.0 ± 9.9 60.4 ± 8.1# 19.6 ± 6.2** 45.5 ± 7.4 17.9 ± 2.4** HTR 108.2 ± 3.1 74.6 ± 9.3# 114.4 ± 10.3** 90.2 ± 7.0 99.8 ± 6.4* Glucose 215.3 ± 27.3 238.7 ± 23.4 190.3 ± 19.5 223.0 ± 22.5 193.3 ± 18.7 Insulin 0.043 ± 0.015 0.191 ± 0.064# 0.037 ± 0.010** 0.080 ± 0.015** 0.042 ± 0.013** HOMA-IR 0.40 ± 0.09 2.09 ± 0.95# 0.32 ± 0.11** 0.79 ± 0.19* 0.35 ± 0.06** AST 90.2 ± 4.4 168.5 ± 9.3# 122.1 ± 6.1** 110.6 ± 7.3** 113.3 ± 6.6** ALT 28.2 ± 2.3 39.9 ± 3.2# 35.3 ± 2.8 31.4 ± 3.3* 30.3 ± 2.9* TP 5.30 ± 0.60 5.33 ± 0.40 5.20 ± 0.44 5.37 ± 0.38 5.43 ± 0.55 Albumin 2.40 ± 0.30 2.67 ± 0.12 2.46 ± 0.32 2.70 ± 0.26 2.71 ± 0.30 Leptin 5.32 ± 0.88 12.59 ± 2.17# 11.13 ± 1.80 9.82 ± 1.35 8.94 ± 1.02 Adiponectin 6.10 ± 0.32 4.83 ± 0.29 4.95 ± 0.37 5.22 ± 0.24 5.53 ± 0.31 AI 1.38 ± 0.13 2.55 ± 0.19# 0.89 ± 0.12** 1.86 ± 0.09** 0.71 ± 0.03** AC -0.08 ± -0.06 0.35 ± 0.02# -0.12 ± -0.06** 0.10 ± 0.01** 0.01 ± 0.005** CRR 0.92 ± 0.06 1.35 ± 0.04# 0.88 ± 0.06** 1.10 ± 0.08** 1.01 ± 0.07** CAI 0.20 ± 0.04 0.85 ± 0.05# 0.06 ± 0.02** 0.47 ± 0.06** 0.15 ± 0.10** The data are presented as means ± SD, n = 10. One-way ANOVA followed by the post hoc Tukey test. #p < 0.01, compared to Control group. *p < 0.05 and **p < 0.01, compared to DIO group. Feno, fenofibrate; PFV, pomegranates fruits vinegar; CTFV, C. tricuspidata fruits vinegar; TC, total cholesterol (mg/dL); TG, triacylglycerol (mg/dL); HDL, high-density lipoprotein cholesterol (mg/dL); LDL, low-density lipoprotein cholesterol (mg/dL); VLDL, very low-density lipoprotein cholesterol (mg/dL); HTR, HDL/total cholesterol ratio; Glucose, TP (total protein), and albumin (mg/dL); Insulin (ng/mL); HOMA-IR, homeostasis model assessment-insulin resistance; AST, aspartate aminotransferase (U/L); ALT, alanine aminotransferase (U/L); Leptin (ng/mL); Adiponectin (μg/mL); AI, atherogenic index; AC, atherogenic coefficient; CRR, cardiac risk ratio; CAI, coronary artery index. The indices including AI, AC, CRR, and CAI of mice were elevated after HFD feeding compared with the Control group, as shown in Table 7. The increased atherogenic index was strongly decreased in the CTFV group, and elevated values of the atherogenic coefficient, cardiac risk ratio, and coronary artery index were remarkably reduced in the Feno group. Differences in parameters such as glucose, total protein, albumin, leptin, and adiponectin were not significant in the CTFV group and other groups. CTFV efficacy involves alterations in AdipoR1, OBR, IRS1, and PTP1B signaling and its phosphorylation in liver of obese mice To investigate how CTFV altered the activation of receptor genes after HFD feeding, we evaluated the protein expression levels of adiponectin, leptin, and insulin-related genes. We found that HFD feeding downregulated AdipoR1 (Fig. 6C), and OBR (Fig. 6E), and upregulated the levels of PTP1B (Fig. 6H), which is an IR suppressor, and IRS1 phosphorylation (Fig. 6F) compared with the Control group, but no changes in the levels of pOBR (Fig. 6D), and IRS1 (Fig. 6G), as shown in Fig. 6A. Compared with the DIO group, CTFV administration upregulated AdipoR1, OBR, and IRS1 expression and OBR phosphorylation, whereas the expression of PTP1B and IRS1 phosphorylation was downregulated. In the Feno and PFV groups, AdipoR1, OBR, IRS1, and OBR phosphorylation were upregulated and IRS1 phosphorylation and PTP1B were downregulated compared with the DIO group. These results indicate that the regulation of AdipoR1, and OBR expression/activation through CTFV administration coincides with the reduction in HDF-induced initial activation of fatty acid oxidation and lipid synthesis in liver from obese mice.Figure 6 Effects of CTFV, PFV, and fenofibrate on AdipoR1, OBR, IRS1, and PTP1B (A), or PI3K, AKT, ERK, P38, AMPK, and ACC (B) expressions in liver from the obese mice. Each value is the mean ± SD of triplicate measurements. Protein expression was detected by western blotting. #p < 0.01, compared with Control group, *p < 0.05 and **p < 0.01, compared with DIO group, ap < 0.05 and aap < 0.01, compared with DIO + Feno group, bp < 0.01, compared with DIO + PFV group. Control, non-induced normal group; DIO, diet-induced obesity model group; DIO + Feno, fenofibrate-treated DIO group, DIO + PFV, pomegranate fruit vinegar (PFV)-treated DIO group; DIO + CTFV, C. tricuspidata fruit vinegar (CTFV)-treated DIO group. CTFV regulates HDF-induced activation/phosphorylation of PI3K/AKT/MAPKs and AMPK in liver of obese mice We further examined whether CTFV administration contributed to attenuating HDF-induced activation and its underlying mechanisms. Our findings showed that HFD feeding activated the phosphorylation of PI3K/AKT (Fig. 6I–K) and MAPKs, including ERK (Fig. 6M), JNK (Fig. 6N), and P38 (Fig. 6O), and downregulated AMPK (Fig. 6Q), ACC (Fig. 6S), and their phosphorylation (Fig. 6P,R) compared with the Control group (Fig. 6B), but no changes in the level of AKT (Fig. 6L). In the CTFV group, the phosphorylation levels of PI3K/AKT and MAPKs were markedly decreased, and AMPK and its phosphorylation signaling were strongly activated compared with those of the DIO group, but differences in the pACC/ACC levels after CTFV administration were not significant. While Feno administration reduced AKT/pAKT levels and increased AMPK/pAMPK and pACC levels, PFV administration downregulated pAKT and MAPK activation and upregulated pAMPK/AMPK and pACC. These results demonstrate that CTFV administration regulates the underlying mechanisms after HDF-induced stimulation by attenuating the PI3K/AKT/MAPKs pathway and activating AMPK. CTFV controls HDF-induced protein abundance in energy/lipid metabolism in liver of obese mice To investigate how CTFV controls the underlying molecular mechanisms involved in glucose transport, lipid synthesis, and fatty acid oxidation, the protein expression of GLUT4, SREBP1C, PPARα and γ, CEBPα and β, and FAS were determined in the liver of each group. As shown in Fig. 7, the DIO group presented reductions in PPARα and γ expression and elevations in SREBP1C, CEBPα and β, and FAS expression compared with those of the Control group. CTFV administration activated GLUT4 and PPARα expression and attenuated SREBP1C, CEBPα and β, and FAS expression. The upregulation in GLUT4 and PPARα expression and downregulation in CEBPα and β expression were observed in the Feno and PFV groups compared with the DIO group. Moreover, Feno administration inhibited SREBP1C expression, whereas PFV administration strongly inhibited FAS expression. Our findings demonstrate that CTFV administration contributed to the reduction in lipid and fat accumulation by downregulating SREBP1C, CEBPα, CEBPβ, and FAS or by activating GLUT4 and PPARα.Figure 7 Effects of CTFV, PFV, and fenofibrate on GLUT4, SREBP1C, PPARα, PPARγ, CEBPα, CEBPβ, and FAS expressions in liver from the obese mice. Each value is the mean ± SD of triplicate measurements. Protein expression was detected by western blotting. #p < 0.01, compared with Control group, *p < 0.01, compared with DIO group (A), ap < 0.05 and aap < 0.01, compared with DIO + Feno group, bp < 0.01, compared with DIO + PFV group. Control, non-induced normal group; DIO, diet-induced obesity model group; DIO + Feno, fenofibrate-treated DIO group, DIO + PFV, pomegranate fruit vinegar (PFV)-treated DIO group; DIO + CTFV, C. tricuspidata fruit vinegar (CTFV)-treated DIO group. Discussion Vinegar has been used since about 300 BC and is a crucial component for food flavoring and preservation in European, Western, and Asian countries. While vinegar was once used as a simple seasoning, its use has expanded to health-related fields, and its various biological activities are actively undergoing study. Many bio-active ingredients, including amino acids, peptides, carbohydrates, organic acids, minerals, vitamins, and polyphenolics, that are effective for health care have been found in vinegar43–45. In particular, fruit vinegars produced using apples, grapes, pineapples, or berries contain various flavonoids and polyphenolics, and they are known to increase physiological abilities and improve in vitro and in vivo body fat accumulation and overweight states43–47. There are numerous articles regarding the anti-obesity effect of compounds detected from fruit vinegars, including caffeoylsophorose, chlorogenic acid, p-hydroxybenzoic acid, ferulic acid, syringic acid, and catechin46,48–50. For fruit vinegars, the anti-obesity abilities involving lipid or energy metabolism or glucose regulation are mostly due to acetic acid and other major substances. The previous studies demonstrated that acetic acid consumption decreased the blood glucose content and lipid synthesis via activating AMPK and reducing SREBP-1c or PPARγ levels among vinegar components46,47,51,52. Besides acetic acid as the major substance, caffeoylsophorose has an α-glucosidase-inhibitory function and a reductive effect on blood glucose53, while ferulic acid54,55 and syringic acid56,57 suppressed obesity-associated metabolism through reductions in lipogenesis (TG production), fat accumulation (body, hepatic), reactive oxygen species (ROS) accumulation, serum lipids (TC, TG, LDL), and serum inflammation (IL-6, TNF- α) or an increase in lipolysis (glycerol release). In a previous study58, CTFV was examined to establish the conditions of the fermentation process using acetic acid isolated from traditional fermented food, and that article mainly considered the identification of bacterial strains in traditional foods, the chemical properties of vinegar, sensory evaluation, free radical scavenging, and α-glucosidase inhibition assays. The present study is the first to demonstrate the production and physicochemical characteristics of fruit vinegar using C. tricuspidata fruits, the detection of polyphenolic and parishin derivatives from CTFV, the metabolism-associated inhibitory effects of compounds detected in CTFV, and the anti-obesity effects of CTFV against a DIO mouse model. Oxidative metabolisms are involved in the development of obesity. Bioactive adipokines produced from white adipose tissue are linked to the formation of ROS which induces oxidative stress by some mechanisms including the product of free radicals through excessive oxygen consumption, the peroxisomal or mitochondrial oxidation of fatty acids, and consumption of lipid or fat-rich diets59,60. Moreover, obesity and oxidative stress have been related to the development of the metabolic syndromes including insulin resistance, diabetes, systemic arterial hypertension, ischemic heart diseases, obstructive sleep apnea, asthma, gout, peripheral vascular disease, psychology problems, rheumatological problems, oncology problems, and liver failure60. The continuing symptoms of obesity gradually reduce antioxidant capabilities, resulting in reduced activity of antioxidant enzymes such as SOD61, CAT61 and GPx62 and eventually lead to obesity-related complications. In addition, the factors that are being applied as biomarkers for obesity and oxidative stress were reported by MDA60 and NO63. Increased production of superoxide and endothelial NO in obese patients may increase peroxynitrite level, reducing the usability of NO and inducing vasoconstriction in liver blood vessels64. Meanwhile, the decrease in body fat is well known to improve the oxidative parameters, increasing antioxidant capabilities, and these effects have been reported to be due to ingestion of key antioxidant substances such as vitamin C, vitamin E and flavonoids60. The liver play a crucial role in the control of cholesterol, fatty acids, and some metabolites since it manages the reservation and elimination mechanisms through the AMPK/PI3K/AKT/MAPKs/PTP1B multi-pathway, including their underlying molecular signaling pathways. Three different major receptors involved in the energy-regulatory mechanism are AdipoR1, IR, and OBR, which react with their substrates to induce the activation of AMPK/PI3K/AKT/MAPKs and eventually contribute to fatty acid oxidation, lipid synthesis, and glucose uptake65–71. AMPK has been found as a mediator or key enzyme in energy metabolism, lipid homeostasis, and glucose uptake in liver and adipose tissue72,73. AMPK is activated/phosphorylated by fasting or starvation; furthermore, activated AMPK stimulates glucose uptake and lipid oxidation by inactivating 3-hydroxy-3-methylglutaryl CoA reductase and ACC as key metabolic enzymes, and it diminishes glycerolipid synthesis by decreasing the concentration of malonyl CoA74,75. The PI3K/AKT molecular signaling pathway involves several cellular functions via regulating growth factors in cellular development and organismal processes, including cell proliferation, protein synthesis, lipid metabolism, and glucose homeostasis76. The liver reacts closely with insulin through decreasing glucose levels, and the feeding state induces reductions in hepatic glucose production and increases in the synthesis of fatty acids and glycogen synthesis via PI3K/AKT/GLUT4 or PI3K/AKT/SREBP-1c signaling77–79. SREBPs are transcription factors that control gene expression in the biosynthesis of phospholipids, triglycerides, fatty acids, and cholesterol; particularly, SREBP-1c mediates genes expression involved in triacylglycerol accumulation and synthesis, including ACC and FAS80,81. SREBP-1c overexpression causes intensive hepatic lipogenesis. AKT modulates the signaling of mammalian target of rapamycin complex 1-p70 ribosomal protein S6 kinase 1 (mTORC1-S6K1) to mediate SREBP-1c expression in the liver and inhibits the expression of insulin-induced gene (INSIG) 2a, which encodes the SREBP-1c inhibitor, via an mTORC1-independent mechanism78. MAPKs such as ERK, JNK, and P38 are involved in the essential processes for cell differentiation and proliferation, are known to contribute to adipocyte differentiation by regulating C/EBPα and PPARγ expression, and are phosphorylated through IR and IRS1/2, which are activated by increasing glucose and insulin as adipogenic stimuli82,83. PTP-1B is a negative regulator of IR signal transduction and a potential target for the treatment of metabolic diseases, including type 2 diabetes and obesity84. Mice lacking PTP1B are hypersensitive to leptin resistance, obesity, and insulin level85. The signaling pathways induced by adipocytokines and adipogenic stimuli eventually contribute to controlling the signal transductions of PTP1B, ACC, SREBP, GLUT, PPAR, C/EBP, and FAS to regulate insulin or leptin signaling, fatty acid oxidation, glucose uptake, lipid synthesis, and adipose differentiation. In the present study, HFD feeding for 50 days caused phenotypic changes including hyperlipidemia, hepatic steatosis, and increased adiposity and liver mass similar to those found in previous studies36,86–88. HFD feeding increased the body weight gain by 2.11-fold, body fats (epididymal, perirenal, and mesenteric) by 3.15–4.40-fold, hepatic fat mass by 1.34-fold, and adipocyte size by 2.01-fold compared to mice fed a normal diet, and these changes might be correlated with hypercholesterolemia, hypertriglyceridemia, hepatomegaly, insulin resistance, and cardiovascular-related risk indices. Our findings reveal that HFD feeding elevated TC, TG, LDL, insulin resistance, liver mass, and cardiovascular-related risk indices (including AI, AC, CRR, CAI) by 1.55, 2.01, 4.59, 5.23, 1.67, and 1.47–4.25-fold, respectively, compared to the normal mice. Moreover, liver function tests for biochemical abnormalities, a rise in leptin level, reduction in adiponectin level, changes in obesity-associated metabolizing enzyme activities, and oxidative damages were observed in liver and serum from the obese mice model. According to the present findings, CTFV surpassed PFV (functional foods to help reduce body fat) and fenofibrate (a lipid-lowering drug) in reducing body weight gain, hepatic fat or mass, body fats, adipocyte size, serum or liver triacylglycerol, leptin, the atherogenic index, and nitrite, as well as in increasing adiponectin and SOD. The possible mechanisms of the strong anti-obesity ability of CTFV might be due to the presence of metabolites and substances such as chlorogenic acid, caffeic acid, rutin, gastrodin, 4-hydroxybenzoic acid, parishin A, and acetic acid in CTFV, which were known to have anti-oxidative32,89,90, anti-obesity11,18,90–95, cardio-protective89,95, and anti-inflammatory effects11,95. Liver steatosis and nonalcoholic fatty liver are the most common chronic liver disease. In previous studies96,97, fatty liver is commonly caused by high-carbohydrate or high-fat ingestion, hormonal manipulation, and dietary methionine restriction. Low steady-state TG levels of liver on physiological condition were maintained by balancing between accumulation and disposal. Under conditions of increased nutrition and insulin resistance, the balance is destructed by various factors that increase the concentration of TGs and VLDLs in the liver, which in turn results in liver steatosis. Our findings show HFD-induced increased levels of TC, TH, LDL, and VLDL resulted in hepatic steatosis and increase in hepatic TG level. Moreover, the lipid accumulation in the liver can be caused by four different metabolic reactions: decreased oxidation of hepatic fatty acids, increase in transference of fatty acids (TG in adipose cells, dietary lipids, hepatic de novo lipogenesis) to hepatocytes, inadequate secretion of neutral fats in VLDL, and increased synthesis of TG98. Recently, anti-obesity studies have concentrated on testing for reductions in the activities of obesity-associated metabolizing enzymes, because inhibiting these enzymatic activities in energy/carbohydrate/lipid metabolisms can reduce metabolite usage and absorption by activating thermogenesis and lipolysis and by inhibiting fatty acid formation and digestive activities28,30,99,100. Here, our findings demonstrated that CTFV and its phytophenolics including chlorogenic acid, caffeic acid, rutin, gastrodin, 4-hydroxybenzoic acid, and parishin A inhibited the obesity-related metabolizing enzymes of lipase, β-glucosidase, α-amylase, citrate synthase, and alkaline phosphatase in vitro, suggesting that CTFV treatment reduced lipid-hydrolyzing activity, triacylglycerol hydrolysis101, glycogenolysis102, glucose absorption33, the initial material concentration for fatty acid synthesis30, and lipid absorption or transport103. Although CTFV induced mean decreases in enzymatic activities in vivo, there were some differences compared with the effects in vitro. CTFV administration showed significant inhibitory effects in vivo against the activities of pancreatic lipase and alkaline phosphatase in serum and α-amylase and lipoprotein lipase in liver from the HFD-induced obese mice model. The difference between the in vitro or in vivo effects is not understood; however, these results suggest that trace amounts of phytophenolics present in CTFV are transported to the liver through the bloodstream; then, they partially influence enzyme activity in the blood and liver of the obese mice104. In addition, the immunoblotting results demonstrated that the effects of CTFV contributed AMPK activation, and reduction of initial activation of fatty acid oxidation and lipid synthesis, phosphorylation stimulation, and lipid or fat accumulation by influencing hepatic AdipoR1, OBR, IRS1, PTP1B, PI3K/AKT/MAPKs, AMPK, and various signaling transductions. In conclusion, the present study demonstrated that CTFV inhibited the HFD-induced increases in body weight, feed efficiency, body fat mass, adipose cell size, and serum or liver lipids by regulating signal transduction mechanisms related to adipogenesis, fatty acid oxidation, and glucose transport and by mediating obesity-associated enzymatic activities and the antioxidant ability in liver or serum. Therefore, we suggest that CTFV might be beneficial for improving HFD-induced obesity and for developing functional food ingredients with an anti-obesity ability. Supplementary information Supplementary Information. Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Supplementary information is available for this paper at 10.1038/s41598-020-78166-9. Acknowledgements This research was supported by development of techniques for export of fermented vinegar with functional fruits (PJ012588032020) from Rural Development Administration (RDA), Republic of Korea. This study was conducted by research funds from Gwangju University, Republic of Korea in 2020 (2020G1). Author contributions S.K., and J.H.C. designed the experiments. S.Y.H., and M.K.K. analyzed the phenolic compounds, and produced the CTFV. J.H.C. performed the animal and in vitro experiments. S.K., M.K.K., and J.H.C. performed data analysis. S.Y.H. support the research items. J.H.C. wrote the paper. All authors read and approved the final manuscript. Competing interests The authors declare no competing interests. ==== Refs References 1. Stoner L Cornwall J Did the American Medical Association make the correct decision classifying obesity as a disease? Austral. Med. J. 2014 7 462 464 10.4066/AMJ.2014.2281 2. Srivastava G Apovian CM Current pharmacotherapy for obesity Nat. Rev. Endocrinol. 2018 14 12 24 10.1038/nrendo.2017.122 29027993 3. Štimac D Klobučar Majanović S Belančić A Endoscopic treatment of obesity: From past to future Dig. Dis. 2020 6 1 13 4. Chae H Relationships between obesity, body image perception, and weight control in adult women Korean J. Women Health Nurs. 2019 25 129 142 10.4069/kjwhn.2019.25.2.129 5. Mohamed GA Ibrahim SRM Elkhayat ES Dine RSE Natural anti-obesity agents Bull. Fac. Pharm. Cairo Univ. 2014 52 269 284 10.1016/j.bfopcu.2014.05.001 6. Anyanwu GO Kolb AF Bermano G Phytochemicals as Lead Compounds for New Drug Discovery 2020 Amsterdam Elsevier 143 160 7. Kwak NS Kim E Kim HR Current status and improvements of obesity related legislation Korean J. Nutr. 2010 43 413 423 10.4163/kjn.2010.43.4.413 8. Korean National Statistical Office. Mortality per 100,000 people per cause of death statistics. http://www.kostat.go.kr (2017). 9. Park CM Yoon HS Blood glucose control and increase immunity effects of β-glucan added cooked barley noodle in high-fat diet and streptozotocin-induced diabetic mice J. Korean Soc. Integr. Med. 2018 6 89 98 10. Kang NY Jung BM Analysis of the difference in nutrients intake, dietary behaviors and food intake frequency of single- and non-single-person households: The Korea National Health and Nutrition Examination Survey (KNHANES), 2014–2016 Korean J. Community Nutr. 2019 24 1 17 10.5720/kjcn.2019.24.1.1 11. Korean National Statistical Office. Medical expenses statistics. http://www.kostat.go.kr (2013–2017). 12. Jeong YJ Current trends and future prospects in the Korean vinegar industry Food Sci. Ind. 2009 42 52 59 13. Choi CY Park EH Ryu SJ Shin WC Kim MD Metabolome analysis and aroma characteristics of fermented fruit vinegar Microbiol. Biotechnol. Lett. 2018 46 416 424 10.4014/mbl.1806.06012 14. Ok E Pomegranate vinegar attenuates adiposity in obese rats through coordinated control of AMPK signaling in the liver and adipose tissue Lipids Health Dis. 2013 12 163 10.1186/1476-511X-12-163 24180378 15. Park JE Pomegranate vinegar beverage reduces visceral fat accumulation in association with AMPK activation in overweight women: A double-blind, randomized, and placebo-controlled trial J. Funct. Foods 2014 8 274 281 10.1016/j.jff.2014.03.028 16. Setorki M Nazari B Asgary S Azadbakht L Rafieian-Kopaei M Anti-atherosclerotic effects of verjuice on hypocholesterolemic rabbits Afr. J. Pharm. Pharmacol. 2011 5 1038 1045 17. Beh BK Anti-obesity and anti-inflammatory effects of synthetic acetic acid vinegar and Nipa vinegar on high-fat-diet-induced obese mice Sci. Rep. 2017 7 6664 10.1038/s41598-017-06235-7 28751642 18. Bounihi A Bitam A Bouazza A Yargui L Koceir EA Fruit vinegars attenuate cardiac injury via anti-inflammatory and anti-adiposity actions in high-fat diet-induced obese rats Pharm. Biol. 2017 55 43 52 10.1080/13880209.2016.1226369 27595296 19. Ostman E Granfeldt Y Persson L Björck I Vinegar supplementation lowers glucose and insulin responses and increases satiety after a bread meal in healthy subjects Eur. J. Clin. Nutr. 2005 59 983 988 10.1038/sj.ejcn.1602197 16015276 20. Liatis S Vinegar reduces postprandial hyperglycaemia in patients with type II diabetes when added to a high, but not to a low, glycaemic index meal Eur. J. Clin. Nutr. 2010 64 727 732 10.1038/ejcn.2010.89 20502468 21. Yagnik D Serafin VJ Shah A Antimicrobial activity of apple cider vinegar against Escherichia coli , Staphylococcus aureus and Candida albicans ; downregulating cytokine and microbial protein expression Sci. Rep. 2018 8 1732 10.1038/s41598-017-18618-x 29379012 22. Mohamad NE In vitro and in vivo antitumour effects of coconut water vinegar on 4T1 breast cancer cells Food Nutr. Res. 2019 63 1616 10.29219/fnr.v63.1616 23. Xie H Raw and vinegar processed Curcuma wenyujin regulates hepatic fibrosis via bloking TGF-β/Smad signaling pathways and up-regulation of MMP-2/TIMP-1 ratio J. Ethnopharmacol. 2020 246 111768 10.1016/j.jep.2019.01.045 30849507 24. Zhu W Dietary vinegar prevents kidney stone recurrence via epigenetic regulations EBioMed. 2019 45 231 250 10.1016/j.ebiom.2019.06.004 25. Ali Z Ma H Rashid MT Wali A Younas S Preliminary study to evaluate the phytochemicals and physiochemical properties in red and black date's vinegar Food Sci. Nutr. 2019 7 1976 1985 10.1002/fsn3.1009 31289645 26. Park SY Quality characteristics and antioxidant activity of Bokbunja (black raspberry) vinegars Food Eng. Prog. 2012 16 340 346 27. Oh HH Production of concentrated blueberry vinegar using blueberry juice and its antioxidant and antimicrobial activities J. Korean Soc. Food Sci. Nutr. 2017 46 695 702 28. Lee ES Fermentation characteristics of mulberry (Cudrania tricuspidata ) fruits produced using microbes isolated from traditional fermented food, and development of fermented soybean food Korean J. Food Preserv. 2014 21 866 877 10.11002/kjfp.2014.21.6.866 29. Jo YH Anti-obesity effect of 6,8-diprenylgenistein, an isoflavonoid of Cudrania tricuspidata fruits in high-fat diet-induced obese mice Nutrients 2015 7 10480 10490 10.3390/nu7125544 26694457 30. Choi JH Yeo SH Kim MK Lee HJ Kim S p -Hydroxybenzyl alcohol inhibits four obesity-related enzymes in vitro J. Biochem. Mol. Toxicol. 2018 32 e22223 10.1002/jbt.22223 30273962 31. Baek SY Quality characteristics of fermented vinegar prepared with the detoxified Rhus verniciflua extract J. Korean Soc. Food Preserv. 2015 22 674 682 10.11002/kjfp.2015.22.5.674 32. Kim DW Comparison of bioactive compounds and antioxidant activities of Maclura tricuspidata fruit extracts at different maturity stages Molecules 2019 24 E567 10.3390/molecules24030567 30720740 33. Taslimi P Akıncıoglu H Gülçin İ Synephrine and phenylephrine act as α-amylase, α-glycosidase, acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase enzymes inhibitors J. Biochem. Mol. Toxicol. 2017 31 e21973 10.1002/jbt.21973 34. Choi JH Lee HJ Kim YS Yeo SH Kim S Effects of Maclura tricuspidata (Carr.) Bur fruits and its phytophenolics on obesity-related enzymes J. Food Biochem. 2020 44 e13110 31792999 35. Choi JH Kim S Mechanisms of attenuation of clot formation and acute thromboembolism by syringic acid in mice J. Funct. Foods 2018 43 112 122 10.1016/j.jff.2018.02.004 36. Choi JH Kim DW Kim S Kim SJ In vitro antioxidant and in vivo hypolipidemic effects of the king oyster culinary-medicinal mushroom, Pleurotus eryngii var. ferulae DDL01 (Agaricomycetes), in rats with high-fat diet-induced fatty liver and hyperlipidemia Int. J. Med. Mushrooms 2017 19 107 119 10.1615/IntJMedMushrooms.v19.i2.20 28436319 37. McCord JM Fridovich I Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein) J. Biol. Chem. 1969 244 6049 6055 5389100 38. Choi JH Kim NH Kim SJ Lee HJ Kim S Fucoxanthin inhibits the inflammation response in paw edema model through suppressing MAPKs, Akt, and NFκB J. Biochem. Mol. Toxicol. 2016 30 111 119 10.1002/jbt.21769 26418808 39. Tappel AL Glutathione peroxidase and hydroperoxides Methods Enzymol. 1978 52 506 513 10.1016/S0076-6879(78)52055-7 672654 40. Friedewald WT Levy RI Fredrickson DS Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin. Chem. 1972 18 499 502 10.1093/clinchem/18.6.499 4337382 41. Vogeser M Fasting serum insulin and the homeostasis model of insulin resistance (homa-ir) in the monitoring of lifestyle interventions in obese persons Clin. Biochem. 2007 40 964 968 10.1016/j.clinbiochem.2007.05.009 17583689 42. Ikewuchi CJ Ikewuchi CC Alteration of plasma lipid profiles and atherogenic indices by Stachytarpheta jamaicensis L. (Vahl) Biokemistri. 2009 21 71 77 43. Morales ML Tesfay W Garcia-Barilla MC Cases JA Tronco AM Evaluation of the aroma profile of sherry wine vinegar during an experimental aging lagging in wood J. Agric. Food Chem. 2002 50 3173 3178 10.1021/jf011313w 12009982 44. Johnston CS Kim CM Buller AJ Vinegar improves insulin sensitivity to a high carbohydrate meal in subjects with insulin resistance or type-2 diabetes mellitus Diabetes Care 2004 27 281 282 10.2337/diacare.27.1.281 14694010 45. Cocchia M Simultaneous determination of sugars and organic acids in aged vinegar and chemometric data analysis Talanta 2006 69 1166 1175 10.1016/j.talanta.2005.12.032 18970699 46. Chen H Chen T Giudici P Chen F Vinegar functions on health: Constituents, sources, and formation mechanisms Comp. Rev. Food Sci. Food Saf. 2016 15 1124 1138 10.1111/1541-4337.12228 47. Samad A Azlan A Ismail A Therapeutic effects of vinegar: A review Curr. Opin. Food Sci. 2016 8 56 61 10.1016/j.cofs.2016.03.001 48. de Souza Mesquita LM Modulatory effect of polyphenolic compounds from the mangrove tree Rhizophora mangle L. on non-alcoholic fatty liver disease and insulin resistance in high-fat diet obese mice Molecules 2018 23 2114 10.3390/molecules23092114 49. Wang W Ferulic acid suppresses obesity and obesity-related metabolic syndromes in high fat diet-induced obese C57BL/6J mice Food Agric. Immunol. 2018 29 1116 1125 10.1080/09540105.2018.1516739 50. John CM Arockiasamy S Syringic acid (4-hydroxy-3,5-dimethoxybenzoic acid) inhibits adipogenesis and promotes lipolysis in 3T3-L1 adipocytes Nat. Prod. Res. 2019 10.1080/14786419.2019.1573820 30777451 51. Östman E Granfeldt Y Persson L Björck I Vinegar supplementation lowers glucose and insulin responses and increases satiety after a bread meal in healthy subjects Eur. J. Clin. Nutr. 2005 59 983 988 10.1038/sj.ejcn.1602197 16015276 52. Mitrou P The role of acetic acid on glucose uptake and blood flow rates in the skeletal muscle in humans with impaired glucose tolerance Eur. J. Clin. Nutr. 2015 69 734 739 10.1038/ejcn.2014.289 25626409 53. Matsui T Caffeoylsophorose, a new natural alpha-glucosidase inhibitor, from red vinegar by fermented purple-fleshed sweet potato Biosci. Biotechnol. Biochem. 2004 68 2239 2246 10.1271/bbb.68.2239 15564660 54. Naowaboot J Piyabhan P Munkong N Parklak W Pannangpetch P Ferulic acid improves lipid and glucose homeostasis in high-fat diet-induced obese mice Clin. Exp. Pharmacol. Physiol. 2016 43 242 250 10.1111/1440-1681.12514 26541794 55. Wang W Optimal dietary ferulic acid for suppressing the obesity-related disorders in leptin-deficient obese C57BL/6J -ob/ob mice J. Agric. Food Chem. 2019 67 4250 4258 10.1021/acs.jafc.8b06760 30907082 56. Ham JR Anti-steatotic and anti-inflammatory roles of syringic acid in high-fat diet-induced obese mice Food Funct. 2016 7 689 697 10.1039/C5FO01329A 26838182 57. Srinivasulu C Ramgopal M Ramanjaneyulu G Anuradha CM Suresh Kumar C Syringic acid (SA)—A review of its occurrence, biosynthesis, pharmacological and industrial importance Biomed. Pharmacother. 2018 108 547 557 10.1016/j.biopha.2018.09.069 30243088 58. Yim EJ Fermentation characteristics of mulberry (Cudrania tricuspidata ) fruit vinegar produced by acetic acid bacteria isolated from traditional fermented foods Korean J. Food Preserv. 2015 22 108 118 10.11002/kjfp.2015.22.1.108 59. Esposito K Ciotola M Giugliano D Oxidative stress in the metabolic syndrome J. Endocrinol. Invest. 2006 29 791 795 10.1007/BF03347372 17114909 60. Fernández-Sánchez A Inflammation, oxidative stress, and obesity Int. J. Mol. Sci. 2011 12 3117 3132 10.3390/ijms12053117 21686173 61. Amirkhizi F Is obesity associated with increased plasma lipid peroxidación and oxidative stress in women ARYA Atheroscler. J. 2007 2 189 192 62. Ozata M Increased oxidative stress and hypozincemia in male obesity Clin. Biochem. 2002 35 627 631 10.1016/S0009-9120(02)00363-6 12498997 63. De Souza C Basal endothelial nitric oxide release is preserved in overweight and obese adults Obes. Res. 2005 13 1303 1306 10.1038/oby.2005.157 16129710 64. Dobrian A Schriver S Lynch T Prewitt R Effect of salt on hypertension and oxidative stress in a rat model of diet-induced obesity Am. J. Physiol. Renal. Physiol. 2003 285 619 628 10.1152/ajprenal.00388.2002 65. Fritsche L Weigert C Häring HU Lehmann R How insulin receptor substrate proteins regulate the metabolic capacity of the liver–implications for health and disease Curr. Med. Chem. 2008 15 1316 1329 10.2174/092986708784534956 18537611 66. Schultze SM Hemmings BA Niessen M Tschopp O PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis Expert Rev. Mol. Med. 2012 14 e1 10.1017/S1462399411002109 22233681 67. Frühbeck G Intracellular signalling pathways activated by leptin Biochem. J. 2006 393 7 20 10.1042/BJ20051578 16336196 68. Anubhuti Arora S Leptin and its metabolic interactions: An update Diabetes Obes. Metab. 2008 10 973 993 10.1111/j.1463-1326.2008.00852.x 18284436 69. Park HK Ahima RS Leptin signaling F1000Prime Rep. 2014 6 73 25343030 70. Awazawa M Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway Biochem. Biophys. Res. Commun. 2009 382 51 56 10.1016/j.bbrc.2009.02.131 19254698 71. Zeng L Tang WJ Yin JJ Zhou BJ Signal transductions and nonalcoholic fatty liver: A mini-review Int. J. Clin. Exp. Med. 2014 7 1624 1631 25126158 72. Kahn BB Alquier T Carling D Hardie DG AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism Cell Metab. 2005 1 15 25 10.1016/j.cmet.2004.12.003 16054041 73. Hardie DG Sensing of energy and nutrients by AMP-activated protein kinase Am. J. Clin. Nutr. 2011 93 891S 10.3945/ajcn.110.001925 21325438 74. Ruderman NB Saha AK Vavvas D Witters LA Malonyl-CoA, fuel sensing, and insulin resistance Am. J. Physiol. 1999 276 E1 E18 9886945 75. Wu X Involvement of amp-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes Diabetes 2003 52 1355 1363 10.2337/diabetes.52.6.1355 12765944 76. Abeyrathna P Su Y The critical role of Akt in cardiovascular function Vasc. Pharmacol. 2015 74 38 48 10.1016/j.vph.2015.05.008 77. Kubota N Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding Cell Metab. 2008 8 49 64 10.1016/j.cmet.2008.05.007 18590692 78. Yecies Jessica L Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways Cell Metab. 2011 14 21 32 10.1016/j.cmet.2011.06.002 21723501 79. Li S Involvement of the PI3K/Akt signal pathway in the hypoglycemic effects of tea polysaccharides on diabetic mice Int. J. Biol. Macromol. 2015 81 967 974 10.1016/j.ijbiomac.2015.09.037 26410811 80. Kohjima M SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease Int. J. Mol. Med. 2008 21 507 511 18360697 81. Yuan H Shyy JY Martins-Green M Second-hand smoke stimulates lipid accumulation in the liver by modulating AMPK and SREBP-1 J. Hepatol. 2009 51 535 547 10.1016/j.jhep.2009.03.026 19556020 82. Prusty D Park BH Davis KE Farmer SR Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor gamma (PPARγ) and C/EBPα gene expression during the differentiation of 3T3-L1 preadipocytes J. Biol. Chem. 2002 277 46226 46232 10.1074/jbc.M207776200 12270934 83. Bost F Aouadi M Caron L Binetruy B The role of MAPKs in adipocyte differentiation and obesity Biochimie 2005 87 51 56 10.1016/j.biochi.2004.10.018 15733737 84. Xie L Cellular effects of small molecule PTP1B inhibitors on insulin signaling Biochemistry 2003 42 12792 127804 10.1021/bi035238p 14596593 85. Zabolotny JM PTP1B regulates leptin signal transduction in vivo Dev. Cell 2002 2 489 495 10.1016/S1534-5807(02)00148-X 11970898 86. de Oliveira PR Effects of an extract obtained from fruits of Euterpe oleracea Mart. in the components of metabolic syndrome induced in C57BL/6J mice fed a high-fat diet J. Cardiovasc. Pharmacol. 2010 56 619 626 10.1097/FJC.0b013e3181f78da4 20838232 87. Fraulob JC Souza-Mello V Aguila MB Mandarim-de-Lacerda CA Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet Clin. Sci. (Lond.) 2012 123 259 270 10.1042/CS20110373 22420611 88. de Oliveira PR Euterpe oleracea Mart.-derived polyphenols protect mice from diet-induced obesity and fatty liver by regulating hepatic lipogenesis and cholesterol excretion PLoS ONE 2015 10 e0143721 10.1371/journal.pone.0143721 26630290 89. Agunloye OM Cardio-protective and antioxidant properties of caffeic acid and chlorogenic acid: Mechanistic role of angiotensin converting enzyme, cholinesterase and arginase activities in cyclosporine induced hypertensive rats Biomed. Pharmacother. 2019 109 450 458 10.1016/j.biopha.2018.10.044 30399581 90. Ahmad O Lipid modulating anti-oxidant stress activity of gastrodin on nonalcoholic fatty liver disease larval zebrafish model Int. J. Mol. Sci. 2019 20 E1984 10.3390/ijms20081984 31018538 91. Meng S Cao J Feng Q Peng J Hu Y Roles of chlorogenic acid on regulating glucose and lipids metabolism: A review Evid. Based Complement Alternat. Med. 2013 2013 801457 24062792 92. Varshney R Mishra R Das N Sircar D Roy P A comparative analysis of various flavonoids in the regulation of obesity and diabetes: An in vitro and in vivo study J. Funct. Foods 2019 59 194 205 10.1016/j.jff.2019.05.004 93. Karri S Sharma S Hatware K Patil K Natural anti-obesity agents and their therapeutic role in management of obesity: A future trend perspective Biomed. Pharmacother. 2019 110 224 238 10.1016/j.biopha.2018.11.076 30481727 94. Zhao Y Zhang X Interactions of tea polyphenols with intestinal microbiota and their implication for anti-obesity J. Sci. Food Agric. 2019 10.1002/jsfa.10049 31756772 95. Gosslau A Ho CT Li S The role of rutin and diosmin, two citrus polyhydroxyflavones in disease prevention and treatment J. Food Bioact. 2019 5 43 56 10.31665/JFB.2019.5177 96. Cohen JC Horton JD Hobbs HH Human fatty liver disease: Old questions and new insights Science 2011 332 1519 1523 10.1126/science.1204265 21700865 97. Kawano Y Cohen DE Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease J. Gastroenterol. 2013 48 434 441 10.1007/s00535-013-0758-5 23397118 98. Nagle CA Klett EL Coleman RA Hepatic triacylglycerol accumulation and insulin resistance J. Lipid Res. 2009 50 S74 S79 10.1194/jlr.R800053-JLR200 18997164 99. Lallès JP Intestinal alkaline phosphatase: Multiple biological roles in maintenance of intestinal homeostasis and modulation by diet Nutr. Rev. 2010 68 323 332 10.1111/j.1753-4887.2010.00292.x 20536777 100. Wouters EF Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus J. Clin. Endocrinol. Metab. 2012 97 E1720 E1725 10.1210/jc.2011-2886 22723325 101. Adan RA Mechanisms underlying current and future anti-obesity drugs Trends Neurosci. 2013 36 133 140 10.1016/j.tins.2012.12.001 23312373 102. Pandey S Sree A Dash SS Sethi DP Chowdhury L Diversity of marine bacteria producing beta-glucosidase inhibitors Microb. Cell Fact. 2013 12 35 10.1186/1475-2859-12-35 23590573 103. Nakano T Disruption of the murine intestinal alkaline phosphatase gene Akp3 impairs lipid transcytosis and induces visceral fat accumulation and hepatic steatosis Am. J. Physiol. Gastrointest. Liver Physiol. 2007 292 G1439 G1449 10.1152/ajpgi.00331.2006 17332477 104. Barros, H. D. F. Q. & Maróstica, M. R. Chapter 6 Phenolic compound bioavailability using in vitro and in vivo models. In Bioactive Compounds. 113–126, 10.1016/b978-0-12-814774-0.00006-2 (2019).